Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80—results from a single-center survey
Uloženo v:
| Název: | Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80—results from a single-center survey |
|---|---|
| Autoři: | Felix Freudenberger, Anke Ohler, Matthias Theobald, Georg Hess |
| Přispěvatelé: | Johannes Gutenberg-Universität Mainz |
| Zdroj: | Ann Hematol |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2021. |
| Rok vydání: | 2021 |
| Témata: | Male, 610 Medizin, Kaplan-Meier Estimate, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Antineoplastic Combined Chemotherapy Protocols, Humans, Anthracyclines, 10. No inequality, Cyclophosphamide, Aged, Aged, 80 and over, ddc:610, Age Factors [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Aggressive lymphoma, Progression-Free Survival [MeSH], Rituximab/administration, Cyclophosphamide/administration, Original Article, Male [MeSH], Doxorubicin/administration, Geriatric patients, Combined Modality Therapy [MeSH], Treatment, Lymphoma, Large B-Cell, Diffuse/radiotherapy [MeSH], Radiotherapy, Adjuvant [MeSH], Vincristine/administration, Anthracyclines/administration, Female [MeSH], Lymphoma, Large B-Cell, Diffuse/drug therapy [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Lymphoma, Large B-Cell, Diffuse/epidemiology [MeSH], Antineoplastic Combined Chemotherapy Protocols/administration, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Prednisone/administration, Prognosis [MeSH], Lymphoma, Large B-Cell, Diffuse/mortality [MeSH], Age Factors, Prognosis, Combined Modality Therapy, Progression-Free Survival, 3. Good health, Treatment Outcome, Doxorubicin, Vincristine, Prednisone, Female, Radiotherapy, Adjuvant, Lymphoma, Large B-Cell, Diffuse, Rituximab |
| Popis: | The prognosis of elderly patients diagnosed with diffuse large B cell lymphoma (DLBCL) is considered to be clearly inferior to that of younger patients. Besides tumor biology and comorbidities, treatment selection due to an assumed reduced tolerability may contribute to this difference. With increasingly more patients diagnosed at advanced age, current treatment selections need to be reviewed carefully. Hence, we analyzed the results of patients above the age of 70 in whom a diagnosis of DLBCL was made. Whereas patients up to 80 were frequently selected for and were able to tolerate standard treatment (86% intended use, 74% completion), patients above the age of 80 years were not only treated more cautiously (67 and 60%, respectively) but did show inferior response to treatment with standard treatment (CR rate for intended R-CHOP use 64% vs. 43%). However, on an individual level, patients receiving and completing standard treatment obtained results that resemble the results of younger patients, irrespective if aged more than 80 and impose superior to prior reports in this age cohort. Median PFS for the entire group of patients was 3.44 years, with 4.83 years for patients below 80 and only 1.09 years for patients above the age of 80. The corresponding figures for OS were 7.38 years (estimated); after 2 years, OS was 81% in the younger cohort in contrast to 68% in patients > 80 years. However, for patients not planned to receive or not tolerating R-CHOP, results remain poor; tailored approaches for these patients are required. |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-021-04461-8 |
| DOI: | 10.25358/openscience-7599 |
| Přístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s00277-021-04461-8.pdf https://pubmed.ncbi.nlm.nih.gov/33634349 https://europepmc.org/article/PMC/PMC7960616 https://link.springer.com/content/pdf/10.1007/s00277-021-04461-8.pdf https://www.scilit.net/article/de6c3d353b302183ddfc22f07783f793?action=show-references https://pubmed.ncbi.nlm.nih.gov/33634349/ https://paperity.org/p/261027685/cure-rate-in-the-elderly-patients-with-diffuse-large-b-cell-lymphoma-deteriorates-after https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960616 https://repository.publisso.de/resource/frl:6447851 |
| Rights: | CC BY |
| Přístupové číslo: | edsair.doi.dedup.....02b2383377b64fe1f6db650da7621ecd |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | The prognosis of elderly patients diagnosed with diffuse large B cell lymphoma (DLBCL) is considered to be clearly inferior to that of younger patients. Besides tumor biology and comorbidities, treatment selection due to an assumed reduced tolerability may contribute to this difference. With increasingly more patients diagnosed at advanced age, current treatment selections need to be reviewed carefully. Hence, we analyzed the results of patients above the age of 70 in whom a diagnosis of DLBCL was made. Whereas patients up to 80 were frequently selected for and were able to tolerate standard treatment (86% intended use, 74% completion), patients above the age of 80 years were not only treated more cautiously (67 and 60%, respectively) but did show inferior response to treatment with standard treatment (CR rate for intended R-CHOP use 64% vs. 43%). However, on an individual level, patients receiving and completing standard treatment obtained results that resemble the results of younger patients, irrespective if aged more than 80 and impose superior to prior reports in this age cohort. Median PFS for the entire group of patients was 3.44 years, with 4.83 years for patients below 80 and only 1.09 years for patients above the age of 80. The corresponding figures for OS were 7.38 years (estimated); after 2 years, OS was 81% in the younger cohort in contrast to 68% in patients > 80 years. However, for patients not planned to receive or not tolerating R-CHOP, results remain poor; tailored approaches for these patients are required. |
|---|---|
| ISSN: | 14320584 09395555 |
| DOI: | 10.1007/s00277-021-04461-8 |